Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Geron

This article was originally published in The Gray Sheet

Executive Summary

Sale of $25 mil. in zero coupon convertible debentures to an existing institutional investor under an agreement announced June 29 brings total cash on hand to approximately $98 mil. This "should allow us to continue investing in our telomerase drug discovery, stem cell and nuclear transfer development programs," Geron explains. The Menlo Park, California firm stem cell R&D is focused on discovering, developing and commercializing therapeutic and diagnostic products for applications in oncology, research tools for drug discovery and regenerative medicine
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel